In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates | Zendy

Amit Kaushik | Zendy; Nicole C. Ammerman | Zendy; Jin Lee | Zendy; Olumide Martins | Zendy; Barry N. Kreiswirth | Zendy; Gyanu Lamichhane | Zendy; Nicole Parrish | Zendy; Eric L. Nuermberger | Zendy

Open Access

In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates

Author(s) -

Amit Kaushik,

Nicole C. Ammerman,

Jin Lee,

Olumide Martins,

Barry N. Kreiswirth,

Gyanu Lamichhane,

Nicole Parrish,

Eric L. Nuermberger

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02623-18

Subject(s) - microbiology and biotechnology , mycobacterium abscessus , avibactam , antibiotics , beta lactamase inhibitors , biology , lactam , mycobacterium , pseudomonas aeruginosa , bacteria , chemistry , genetics , ceftazidime , stereochemistry

Pulmonary disease due to infection withMycobacterium abscessus complex (MABC) is notoriously difficult to treat, in large part due to the intrinsic resistance of MABC strains to most antibiotics, including β-lactams. MABC organisms express a broad-spectrum β-lactamase that is resistant to traditional β-lactam-based β-lactamase inhibitors but inhibited by a newer non-β-lactam-based β-lactamase inhibitor, avibactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research